Close menu

October 28th, 2022 | 12:54 CEST

BioNTech, Nel ASA and Desert Gold - Ripe for uptrend?

  • Mining
  • Gold
  • Hydrogen
  • Biotechnology
Photo credits:

The profit warning at ITM Power sent shockwaves throughout the hydrogen sector. Does this mean that the friendly development of the Nel share of the past few days has already ended? Analysts see little potential, at least at present, but are optimistic for the long term. Goldman Sachs is also optimistic about the gold price. At least the chances for a rise to over USD 2,000 are better than for a renewed decline. Producers like Barrick Gold should profit from this, and explorers like Desert Gold even disproportionately. At BioNTech, there is currently no impetus for an upward trend, and analysts' price targets diverge considerably. However, rumors from the US are encouraging.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , NEL ASA NK-_20 | NO0010081235 , DESERT GOLD VENTURES | CA25039N4084

Table of contents:

    Desert Gold: Exciting explorer for less than CAD 10 million

    The gold chart gives investors hope. The strong US dollar and rising interest rates are priced in now. In addition, there is hope that we are not far from the top on both. With a view to an impending recession, interest rates could even fall again in the coming year. And the stock market likes to anticipate the future. Accordingly, the current double bottom could be at USD 1,615. Thus, Goldman Sachs sees a significantly greater chance of gold rising above USD 2,000. Even if interest rates continue to rise significantly, they still see gold at USD 1,500.

    This should also mean that the worst is over for mining stocks like Barrick Gold. Those who want to "leverage" the gold price more strongly are turning to explorers such as Desert Gold. The share has lost 35% of its value in the past six months and is now trading at just CAD 0.065. Although operationally, everything is going according to plan. Nevertheless, the Canadians are now valued at less than CAD 10 million. Desert Gold owns one of the largest non-producing land areas in West Africa with the 440 sq km SMSZ project. Barrick Gold, Allied Gold, Endeavour Mining and B2Gold, among others, are already producing in the neighborhood. The Desert Gold project includes measured and indicated mineral resources of nearly 1.1 million ounces. Samples from the Mogoyafara South projection area have recovered between 86% and 88% of the gold from the rock. The next drill program is expected to delineate resources in the Mogoyafara South and Gourbassi West North areas. It is here that the Company expects to find the largest gold deposits. Anyone curious should watch the board presentation from the IIF virtual investor conference (here).

    Nel: ITM Power shocks investors

    Shareholders of hydrogen companies also need strong nerves at the moment. Yesterday, ITM Power again caused shock waves throughout the industry with a profit warning. ITM reported a series of manufacturing problems and delays in tool production and test runs. Accordingly, the share price plummeted by a good 30% yesterday. Nel also lost significantly at first but was able to limit the losses to less than 2% at the close of trading. However, this means the upward trend of the past few days has come to an end for the time being. Despite weak quarterly figures and negative analyst comments, the shares of the Norwegian company were able to gain recently. Investors are clinging to the high order backlog - this does not apply to analysts. Although the high order backlog makes hope for the year 2024 in the view of JPMorgan, for the current and next year, the sales expectations have been scaled back for the time being. Accordingly, JPMorgan rates the Nel share as "Underweight" with a price target of NOK 10. Currently, the share is trading just above NOK 12.

    BioNTech: USD 183 or USD 312? Analysts disagree

    The BioNTech share currently needs more big impulses. The stock has been trading in a range between EUR 120 and EUR 160 for months. According to Berenberg, significantly higher prices could be possible. Although there is still uncertainty as to how the revenues from the Corona vaccine could continue in the coming year, there is an interesting development in the US. BioNTech partner Pfizer has indicated that it will quadruple the price of the Corona vaccine in the US. This could serve as a model for Europe and would enable BioNTech to generate decent revenues even for smaller quantities. Looking at the development pipeline, the analysts remain positive in the long term. Therefore, Berenberg recommends BioNTech shares as a buy and states a price target of USD 312. JPMorgan is considerably more cautious. The analysts of the US bank have reduced the price target from USD 183 to USD 132. In their view, there is great uncertainty in the sales forecast for the coming years. Only with further progress in the immuno-oncology pipeline does the share have above-average development potential again.

    BioNTech is simply lacking momentum at the moment. There is almost only bad operating news coming out of the hydrogen sector at present. The bright long-term prospects for Nel & Co. can only help to a limited extent. The worst could be over for gold. After the double bottom, the bulls are taking courage again. Desert Gold could profit disproportionately from this. Thus, the share seems anything but expensive.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author

    Related comments:

    Commented by Juliane Zielonka on September 29th, 2023 | 07:00 CEST

    Defence Therapeutics, Schott Pharma, Allianz Group: Focus on Innovation, Growth and Portfolio Optimization

    • Biotechnology
    • Pharma
    • Investments

    According to a recent study, biotech company Defence Therapeutics achieves twice the immune response of conventional mRNA therapies with its Accum® mRNA technology. That translates to fewer side effects and a more effective treatment. According to Precedence Research, the market size for mRNA therapeutics is projected to reach approximately USD 137.59 billion by 2032. It is expected to grow at a CAGR of 13.2% from 2023 to 2032. In order to inject these active ingredients, precision-fit medical vials are required, and Schott Pharma is ensuring this with their IPO launched on the German stock exchange this week, which could bring a valuation of around EUR 4 billion. The Allianz Group, on the other hand, is focusing on consolidation, selling its business in the Middle East and thus flushing around EUR 210 million cash into its coffers.


    Commented by Juliane Zielonka on September 28th, 2023 | 09:20 CEST

    First Hydrogen, Siemens Energy, PayPal - Innovative growth with hydrogen and its own currency

    • Hydrogen
    • greenhydrogen
    • Energy
    • renewableenergies

    Global Market Insights forecasts that the parcel delivery vehicle market is expected to reach over USD 210 billion by 2032, driven by the uninterrupted growth of e-commerce. First Hydrogen is a company specializing in sustainable propulsion solutions for such fleet vehicles. Hydrogen-powered vehicles are also currently finding their way onto the streets of India. India is the world's fifth-largest economy and is sending a crucial signal with hydrogen technology. First Hydrogen has positioned itself in a promising market. Siemens Energy is also betting on hydrogen. After the debacle caused by the takeover of the wind energy company Siemens Gamesa, the hydrogen deal with Air Liquide is finally leading to an increase in the share price. At PayPal, the new CEO is a breath of fresh air. The Company is expanding its growth potential in the direction of its own cryptocurrency. Find out what that means for investors here.


    Commented by Nico Popp on September 28th, 2023 | 09:05 CEST

    Germany - Car Country? The exodus begins: Mercedes-Benz, Volkswagen, First Phosphate

    • Mining
    • phosphate
    • Electromobility
    • Energy

    Cars still play a significant role in Germany. Many households have two vehicles, some even more. However, sales of new cars have weakened recently - the question of whether to buy a combustion engine or an electric vehicle, along with inflation, have deterred many buyers. German brand manufacturers are now being attracted to the US. There, they are enticed by subsidies and an intact market. Find out what the latest plans of Mercedes-Benz, Volkswagen, and others entail and which relatively unknown company could benefit.